Thermo Fisher Scientific has good revenue and margin growth prospects ahead and is trading at a discount. See why TMO stock ...

Thermo Fisher Scientific has signed an agreement with Mainz Biomed to develop and launch a next-generation colorectal cancer ...

We came across a bullish thesis on Thermo Fisher Scientific ... range of scientific instruments, equipment, consumables, and ...

Mainz Biomed (MYNZ) announced a collaborative agreement with Thermo Fisher Scientific (TMO), through its subsidiary ... Mainz Biomed’s Next Generation colorectal cancer screening product. The ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against the ...

Thermo Fisher Scientific TMO is preparing to release ... analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services ...

Thermo Fisher Scientific's Q3 revenue of $10.59 billion missed expectations. Adjusted EPS beat estimates but dropped ...

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 ...

(Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world ...

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic ... Seer also announced a ...

Laboratory Products and Services: I project the segment will grow by 9%, in line with historical trends. As such, I calculate Thermo Fisher Scientific’s revenue will grow by 9% organically.

On Wednesday, Thermo Fisher Scientific Inc. (NYSE ... Segment revenues increased 4.2% to $1.13 billion, and Laboratory Products and Biopharma Services segment sales were almost flat at $5.74 ...